Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Position Increased by Channing Capital Management LLC

Channing Capital Management LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 165,561 shares of the company’s stock after purchasing an additional 52 shares during the period. Channing Capital Management LLC’s holdings in Medpace were worth $50,749,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Wellington Management Group LLP grew its holdings in Medpace by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after buying an additional 319,210 shares in the last quarter. Invesco Ltd. grew its stake in shares of Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Medpace in the third quarter worth $30,252,000. International Assets Investment Management LLC increased its holdings in shares of Medpace by 248,773.8% during the fourth quarter. International Assets Investment Management LLC now owns 104,527 shares of the company’s stock valued at $32,041,000 after purchasing an additional 104,485 shares during the period. Finally, Lord Abbett & CO. LLC raised its stake in shares of Medpace by 682.8% during the third quarter. Lord Abbett & CO. LLC now owns 114,588 shares of the company’s stock valued at $27,745,000 after purchasing an additional 99,949 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Robert W. Baird increased their target price on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Guggenheim raised their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and boosted their target price for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Finally, UBS Group raised Medpace from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Insider Buying and Selling

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the sale, the insider now owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The disclosure for this sale can be found here. In the last quarter, insiders have sold 204,442 shares of company stock valued at $82,702,867. 20.30% of the stock is owned by corporate insiders.

Medpace Stock Up 0.4 %

NASDAQ:MEDP traded up $1.50 during trading hours on Friday, reaching $392.57. 133,312 shares of the company’s stock were exchanged, compared to its average volume of 261,284. The company has a market capitalization of $12.16 billion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. Medpace Holdings, Inc. has a 12 month low of $197.39 and a 12 month high of $421.00. The business’s 50-day simple moving average is $398.08 and its two-hundred day simple moving average is $331.78.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The business had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company’s revenue was up 17.7% compared to the same quarter last year. During the same period last year, the company posted $2.27 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.